NioCorp to be added to Russell 3000 Index
NioCorp (NB) announced that it will be added as a member of the broad-market Russell 3000 Index, effective after the U.S. market opens on June 30 as part of the 2025 Russell indexes reconstitution.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
Xenon Pharmaceuticals joins Russell 3000, Russell 2000 Indexes
Xenon Pharmaceuticals (XENE) announced that the company has been added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes as part of the annual reconstitution, effective at the close of U.S. equity markets on Friday, June 27, 2025. The Russell 3000 Index is an equity index that tracks the performance of the largest 3,000 U.S. stocks by market capitalization. The Russell 2000 Index measures the performance of the 2,000 smallest companies within the Russell 3000 Index. Inclusion in the Russell 2000 results in automatic inclusion in the appropriate growth and value style indexes. Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for investment strategies. Approximately $10.6T in assets are benchmarked against Russell U.S. indexes.
Business Wire
a day ago
- Business Wire
SBC Medical added to membership of Russell 3000 ® Index
IRVINE, Calif.--(BUSINESS WIRE)-- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical'), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000 ® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. Membership in the Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. Fiona Bassett, CEO of FTSE Russell, An LSEG Business, comments: 'The Russell indexes have continuously adapted to the evolving dynamic US economy, and it's crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark.' For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website. About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit FTSE Russell. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' 'targets' or 'hopes' or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are accessible on the SEC's website at
Yahoo
2 days ago
- Yahoo
This Under-$5 AI Stock Is Joining the Russell 2000 Index. Should You Buy It Now?
Rezolve Ai (RZLV) is making waves in the AI enterprise software space, as the tech stock joined the Russell 2000 and Russell 3000 indexes effective today, June 27. Valued at a market cap of $614.4 million, Rezolve Ai announced in June that it achieved annual recurring revenue of $70 million and expects to surpass $100 million in ARR by the end of 2025. Its strategic partnerships with tech giants Microsoft (MSFT) and Google (GOOGL)have bolstered Rezolve's credibility. The company integrated its proprietary Brainpowa large language model into Microsoft Azure and expanded distribution through Google Cloud Marketplace, providing scale opportunities. Dear Nvidia Stock Fans, Watch This Event Today Closely 3 ETFs Offering Juicy Dividend Yields of 15% or Higher Nvidia Could Send This AI Networking Stock 6 Feet Underground Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. The Russell index inclusion is noteworthy, as these benchmarks have attracted over $10.6 trillion in institutional assets. The index inclusion increases visibility among institutional investors and can drive the AI stock higher in the near term. CEO Daniel Wagner emphasized that joining the Russell indexes reflects 'rapidly growing investor recognition' of its AI-powered commerce solutions, which target the retail, logistics, and financial services sectors. However, investors should exercise caution when investing in small-cap AI stocks, as volatility remains high amid rising competition. So, let's see if you should buy Rezolve AI stock right now. Rezolve is positioning itself at the forefront of the AI-driven commerce transformation through its comprehensive Brain Suite platform. Its strategic approach centers on its proprietary Brain Suite, featuring three core components: Brain Commerce for AI-powered conversational commerce, Brain Checkout for seamless engagement platforms, and Brain Assistant for intelligent knowledge management. This integrated approach addresses critical pain points in the e-commerce customer journey, from initial search to final transaction. Its partnerships with Microsoft and Google provide leverage, as cloud customers can apply their existing commitments toward Rezolve subscriptions while sales teams receive incentives to promote the Brain Suite. Rezolve's collaboration with Tether (USDTUSD) to develop merchant-friendly cryptocurrency payment solutions should eliminate transaction fees while expanding payment options. This initiative could disrupt the traditional payments landscape and create additional revenue streams. Rezolve has strengthened its capital structure by eliminating convertible debt and securing a $30 million bank facility, providing the financial runway necessary for aggressive expansion. While Rezolve reported an EBITDA loss of $44 million in 2024, it expects to break even in 2025. Rezolve AI represents a compelling growth story in the rapidly expanding AI solutions market, targeting the estimated $480 billion to $540 billion global opportunity for generative AI. Each of the five analysts covering RZLV stock recommends a 'Strong Buy.' The analysts have an average stock price target of $5.65 for the tech stock, 110% above the current price. On the date of publication, Aditya Raghunath did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
